Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Sep;7(9):745-752.
doi: 10.1016/j.oret.2023.04.014. Epub 2023 May 3.

Levodopa Is Associated with Reduced Development of Neovascular Age-Related Macular Degeneration

Affiliations
Randomized Controlled Trial

Levodopa Is Associated with Reduced Development of Neovascular Age-Related Macular Degeneration

Max J Hyman et al. Ophthalmol Retina. 2023 Sep.

Abstract

Objective: To determine whether levodopa (L-DOPA) is associated with a reduced likelihood of developing neovascular age-related macular degeneration (AMD).

Design: Three studies were performed: retrospective analyses in the Vestrum Health Retina Database (#1-2) and case-control analysis in the Merative MarketScan Research Databases (#3).

Participants: Eyes with neovascular AMD and 2 years of follow-up (#1). Eyes with non-neovascular AMD and 1 to 5 years of follow-up (#2). Patients aged ≥ 55 years with newly diagnosed neovascular AMD matched to controls without neovascular AMD (#3).

Methods: Eyes were divided into 2 groups (#1-2): exposed to L-DOPA before or on the date of neovascular (#1) or nonneovascular (#2) AMD diagnosis, and eyes not exposed to L-DOPA. We extracted AMD risk factors, number of intravitreal injections (#1), and conversion rate to neovascular AMD (#2). We calculated the percentage of newly diagnosed neovascular AMD cases and matched controls exposed to any L-DOPA and determined the cumulative 2-year dose in grams by tertiles (< 100 mg, approximately 100-300 mg, and approximately > 300 mg per day, #3).

Main outcome measures: Number of intravitreal injections (#1) and detection of new-onset neovascular AMD (#2-3) after adjusting for AMD risk factors.

Results: In the Vestrum database, eyes with neovascular AMD that were exposed to L-DOPA underwent 1 fewer intravitreal injection over 2 years (N = 84 088 control vs. 530 L-DOPA eyes, P = 0.006). In eyes with nonneovascular AMD (N = 42 081-203 155 control vs. 314-1525 L-DOPA eyes), L-DOPA exposure was associated with a reduced risk of conversion to neovascular AMD by 21% at year 2 (P = 0.029), 35% at years 3 to 4 (P < 0.001), and 28% at year 5 (P = 0.024). In the MarketScan databases (N = 86 900 per group), cumulative 2-year doses of L-DOPA between approximately 100 to 300 mg per day and approximately > 300 mg were associated with decreased odds of developing neovascular AMD by 15% (odds ratio [OR], 0.85; 95% confidence interval [CI], 0.75-0.97) and 23% (OR, 0.77; 95% CI, 0.67-0.87), respectively.

Conclusions: Levodopa use was associated with reduced detection of new-onset neovascular AMD. A prospective, randomized clinical trial should be considered to investigate whether low-dose L-DOPA reduces neovascular AMD conversion.

Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Keywords: Age-related macular degeneration; Levodopa; Neovascular age-related macular degeneration; Parkinson's disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: no conflicting relationship exists for any author

Figures

Figure 1.
Figure 1.. L-DOPA reduces the risk of conversion to neovascular AMD.
A: Odds ratio and 95% confidence intervals for the risk of conversion to neovascular AMD in eyes exposed to L-DOPA over years 1–5 in the Vestrum database study. B: Odds ratio and 95% confidence intervals for the odds of developments of neovascular AMD in patients exposed to different L-DOPA doses in the MarketScan database study.

References

    1. Group A-REDSR. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol-chic. 2001;119:1417–1436. - PMC - PubMed
    1. Group A-REDS 2 R. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. Jama. 2013;309:2005–2015. - PubMed
    1. Figueroa AG, McKay BS. A G-Protein Coupled Receptor and Macular Degeneration. Cells. 2020;9:910. - PMC - PubMed
    1. Weiter JJ, Delori FC, Wing GL, Fitch KA. Retinal pigment epithelial lipofuscin and melanin and choroidal melanin in human eyes. Invest Ophth Vis Sci. 1986;27:145–52. - PubMed
    1. Lopez VM, Decatur CL, Stamer WD, et al. L-DOPA Is an Endogenous Ligand for OA1 Barsh GS, ed. PLoS Biol. 2008;6:e236–9. - PMC - PubMed

Publication types

LinkOut - more resources